Indications: Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome. Available strengths: 2mg and 4mg x 28 prolonged-release capsules. Dosage and method of use: 4mg once daily except in patients with impaired liver or kidney function for whom recommended dose is 2mg once daily. In case of troublesome adverse reactions dose may be reduced from 4mg to 2mg once daily. Effect of treatment should be re-evaluated after 2-3 months. Take capsules with or without food and swallow whole. Not recommended for children. Contraindications: Hypersensitivity to the active substance or any excipient, urinary retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe ulcerative colitis, toxic megacolon. Special warnings and precautions for use: Use with caution in patients with significant bladder outlet obstruction at risk of urinary retention, gastrointestinal obstructive disorders, renal impairment, hepatic disease, autonomic neuropathy, hiatus hernia, at risk of decreased gastrointestinal motility, risk factors for QT prolongation including: congenital or documented acquired QT prolongation, electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia, bradycardia, relevant pre-existing cardiac diseases, concomitant administration of drugs known to prolong QT-interval including Class IA and Class III anti- arrhythmics. Avoid concomitant treatment with potent CYP3A4 inhibitors. Consider organic reasons for urge and frequency before treatment. Capsules contain lactose and sodium. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.